TABLE 2.
In vitro susceptibilities to fluconazole, itraconazole, and BMS-207147 of bloodstream isolates of Candida spp. from 1997 and 1998
| Species (no. of isolates tested) and antifungal agent | MIC (μg/ml)
|
% Rc | |
|---|---|---|---|
| 50%a | 90%b | ||
| C. albicans (341) | |||
| Fluconazole | 0.25 | 0.5 | 0.9 |
| Itraconazole | 0.03 | 0.12 | 1.5 |
| BMS-207147 | 0.007 | 0.03 | |
| C. glabrata (106) | |||
| Fluconazole | 8 | 16 | 5.7 |
| Itraconazole | 0.5 | 2 | 34.9 |
| BMS-207147 | 0.25 | 1 | |
| C. parapsilosis (97) | |||
| Fluconazole | 0.5 | 2 | 0 |
| Itraconazole | 0.12 | 0.25 | 0 |
| BMS-207147 | 0.03 | 0.06 | |
| C. tropicalis (49) | |||
| Fluconazole | 0.5 | 2 | 0 |
| Itraconazole | 0.12 | 0.25 | 4.1 |
| BMS-207147 | 0.03 | 0.12 | |
| C. guilliermondii (10) | |||
| Fluconazole | 2 | 4 | 0 |
| Itraconazole | 0.25 | 1 | 20 |
| BMS-207147 | 0.12 | 0.25 | |
| C. krusei (10) | |||
| Fluconazole | 32 | 64 | 100 |
| Itraconazole | 0.5 | 2 | 40 |
| BMS-207147 | 0.25 | 0.5 | |
| Total (613) | |||
| Fluconazole | 0.5 | 8 | 1.8 |
| Itraconazole | 0.06 | 0.5 | 8.2 |
| BMS-207147 | 0.015 | 0.25 | |
a
50%, MIC50.
b
90%, MIC90.
c
Based on NCCLS breakpoints (7). All C. krusei isolates are considered fluconazole R.